» Articles » PMID: 3433289

Acute Pulmonary Response of Asthmatics to 3.0 Ppm Formaldehyde

Overview
Publisher Sage Publications
Date 1987 Dec 1
PMID 3433289
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have failed to demonstrate bronchoconstriction in unselected asthmatics after brief (less than or equal to 1/2-h), controlled exposures to formaldehyde (HCHO). This study was designed to evaluate the acute pulmonary response to 3 ppm HCHO in nine nonsmoking asthmatic volunteers over a more relevant exposure duration (3 hrs). Pulmonary function, nonspecific airway reactivity and symptoms were assessed before and at intervals during the exposure. No significant changes in pulmonary function (FVC, FEV1, FEF25-27%, SGaw, or FRC) or airway reactivity were observed. There was a significant increase in nose/throat irritation at 30 min. (P less than 0.05) and in eye irritation at 60 min (P less than 0.05) and 180 min (P less than 0.01). These results suggest that individuals with asthma will not experience significant bronchoconstriction when exposed at rest to 3 ppm HCHO; however, most will experience eye and upper respiratory tract irritation.

Citing Articles

Formaldehyde and asthma: a plausibility?.

Wolkoff P Arch Toxicol. 2025; 99(3):865-885.

PMID: 39828805 DOI: 10.1007/s00204-024-03946-5.


Exposure to formaldehyde and asthma outcomes: A systematic review, meta-analysis, and economic assessment.

Lam J, Koustas E, Sutton P, Padula A, Cabana M, Vesterinen H PLoS One. 2021; 16(3):e0248258.

PMID: 33788856 PMC: 8011796. DOI: 10.1371/journal.pone.0248258.


Indoor Air Quality and Asthma: Has Unrecognized Exposure to Acrolein Confounded Results of Previous Studies?.

Golden R, Holm S Dose Response. 2017; 15(1):1559325817691159.

PMID: 28250718 PMC: 5318801. DOI: 10.1177/1559325817691159.


Mandibular bone necrosis after use of paraformaldehyde-containing paste.

Lee C, Choi Y, Park S Restor Dent Endod. 2016; 41(4):332-337.

PMID: 27847756 PMC: 5107436. DOI: 10.5395/rde.2016.41.4.332.


Does industry take the susceptible subpopulation of asthmatic individuals into consideration when setting derived no-effect levels?.

Johansson M, Johanson G, Oberg M, Schenk L J Appl Toxicol. 2016; 36(11):1379-91.

PMID: 27283874 PMC: 5089668. DOI: 10.1002/jat.3352.